Early Detection of High-grade Tubal Serous Carcinoma in Women at Low Risk for Hereditary Breast and Ovarian Cancer Syndrome by Systematic Examination of Fallopian Tubes Incidentally Removed During Benign Surgery

Early detection of sporadic pelvic serous carcinoma remains an elusive goal. In women at high risk for hereditary breast and ovarian cancer syndrome who undergo prophylactic salpingectomy, systematic pathologic examination of the fallopian tubes will detect occult tubal cancer, mostly in the fimbriae, of a minority of women. Such tubal cancers are the putative precursor to advanced-stage pelvic cancer. We hypothesized that early tubal cancer detection can also be accomplished in women at low risk using a similar approach. In this study, we performed complete and systematic examination of the fallopian tubes removed during surgery performed for benign indications. Among 522 women, 4 cases of serous tubal intraepithelial carcinoma (STIC) were identified. Three of these cases would have gone undetected using the current standard of care of sampling only a single random section of the tube. The fourth case was accompanied by occult ovarian carcinoma. The fimbriae contained STIC in 3 of the 4 cases and atypical mucosa in 1 case in which the STIC was in the nonfimbriated portion of the tube. The morphologic and immunohistochemical features (aberrant p53 and MIB-1) of these STICs were similar to those expected in high-risk women. All 4 patients with STIC underwent BRCA1 and BRCA2 gene testing; no germline mutations were identified in any patient. An additional 11 specimens contained atypical mucosal proliferations that fell short of morphologic and immunohistochemical criteria for STIC. Two of these 11 fulfilled criteria for a serous tubal intraepithelial lesion, and the remaining atypical proliferations exhibited normal p53 and MIB-1. For most specimens, the fimbriae could be completely submitted in 1 or 2 cassettes per tube. These results demonstrate that systematic examination of the tubal fimbriae can serve as a form of early detection of sporadic tubal cancer without incurring significant labor or cost. We propose that the tubal fimbriae should be completely examined in all patients undergoing benign surgery even if there are no clinical features to suggest risk for hereditary breast and ovarian cancer syndrome.

[1]  C. Landen,et al.  The role of the fallopian tube in the origin of ovarian cancer. , 2013, American journal of obstetrics and gynecology.

[2]  Dianne Miller,et al.  Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: the time has come. , 2013, Gynecologic oncology.

[3]  F. Zullo,et al.  Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. , 2013, Gynecologic oncology.

[4]  B. Karlan,et al.  Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. , 2013, Gynecologic oncology.

[5]  J. Sheeder,et al.  Risk-Reducing Salpingectomy as Preventative Strategy for Pelvic Serous Cancer , 2013, International Journal of Gynecologic Cancer.

[6]  A. Mes-Masson,et al.  Surgical implications of the potential new tubal pathway for ovarian carcinogenesis. , 2013, Journal of minimally invasive gynecology.

[7]  J. A. van der Laak,et al.  Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. , 2012, Gynecologic oncology.

[8]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Tinker,et al.  The role of the fallopian tube in ovarian cancer. , 2012, Clinical advances in hematology & oncology : H&O.

[10]  I. Shih,et al.  Validation of an Algorithm for the Diagnosis of Serous Tubal Intraepithelial Carcinoma , 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[11]  P. Dwyer Ovarian cancer and the pelvic floor surgeon: the case for prophylactic bilateral salpingectomy during POP surgery , 2012, International Urogynecology Journal.

[12]  A. Lytwyn,et al.  Frequency of Serous Tubal Intraepithelial Carcinoma in Various Gynecologic Malignancies: A Study of 300 Consecutive Cases , 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[13]  S. Narod,et al.  BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. , 2012, Gynecologic oncology.

[14]  F. McKeon,et al.  BRCA, the Oviduct, and the Space and Time Continuum of Pelvic Serous Carcinogenesis , 2012, International Journal of Gynecologic Cancer.

[15]  I. Shih,et al.  Diagnosis of Serous Tubal Intraepithelial Carcinoma Based on Morphologic and Immunohistochemical Features: A Reproducibility Study , 2011, The American journal of surgical pathology.

[16]  J. Wischhusen,et al.  The post-reproductive Fallopian tube: better removed? , 2011, Human reproduction.

[17]  Sindy Sohr,et al.  p53 Signature and Serous Tubal In-situ Carcinoma in Cases of Primary Tubal and Peritoneal Carcinomas and Serous Borderline Tumors of the Ovary , 2011, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[18]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[19]  D. Oram,et al.  Outcome of risk‐reducing salpingo‐oophorectomy in BRCA carriers and women of unknown mutation status , 2011, BJOG : an international journal of obstetrics and gynaecology.

[20]  Barry Rosen,et al.  Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. , 2011, Gynecologic oncology.

[21]  J. Wischhusen,et al.  The forgotten fallopian tube , 2011, Nature Reviews Cancer.

[22]  Robert L Coleman,et al.  SGO White Paper on ovarian cancer: etiology, screening and surveillance. , 2010, Gynecologic oncology.

[23]  G. Ning,et al.  A Pathologist's Road Map to Benign, Precancerous, and Malignant Intraepithelial Proliferations in the Fallopian Tube , 2010, Advances in anatomic pathology.

[24]  C. Westhoff,et al.  Tubal sterilization trends in the United States. , 2010, Fertility and sterility.

[25]  B. Crawford,et al.  Multistep Level Sections to Detect Occult Fallopian Tube Carcinoma in Risk-reducing Salpingo-oophorectomies From Women With BRCA Mutations: Implications for Defining an Optimal Specimen Dissection Protocol , 2009, The American journal of surgical pathology.

[26]  S. Nakagawa,et al.  Nationwide Use of Laparoscopic Hysterectomy Compared With Abdominal and Vaginal Approaches , 2009, Obstetrics and gynecology.

[27]  M. Nucci,et al.  Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria , 2009, Modern Pathology.

[28]  P. Shaw,et al.  Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers , 2009, Modern Pathology.

[29]  R. Drapkin,et al.  Serous Carcinogenesis in the Fallopian Tube: A Descriptive Classification , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[30]  B. Karlan,et al.  Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. , 2007, Gynecologic oncology.

[31]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[32]  P. Radice,et al.  Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions: Report of 6 Cases and Review of the Literature , 2006, The American journal of surgical pathology.

[33]  Christopher P Crum,et al.  The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.

[34]  J. Krischer,et al.  BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases , 2005, Cancer.

[35]  B. Karlan,et al.  BRCA-Mutation–Associated Fallopian Tube Carcinoma: A Distinct Clinical Phenotype? , 2005, Obstetrics and gynecology.

[36]  S. Lester,et al.  Manual of Surgical Pathology , 2005 .

[37]  P. Neven,et al.  Prophylactic salpingo-oophorectomy in 51 women with familial breast–ovarian cancer: importance of fallopian tube dysplasia , 2005, International Journal of Gynecologic Cancer.

[38]  P. Radice,et al.  Atypical Epithelial Proliferation in Fallopian Tubes in Prophylactic Salpingo-oophorectomy Specimens from BRCA1 and BRCA2 Germline Mutation Carriers , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[39]  T. Colgan Challenges in the Early Diagnosis and Staging of Fallopian-Tube Carcinomas Associated with BRCA Mutations , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[40]  J. Hunt,et al.  Histologic features of surgically removed fallopian tubes. , 2002, Archives of pathology & laboratory medicine.

[41]  P. V. van Diest,et al.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer , 2001, The Journal of pathology.

[42]  B. Rosen,et al.  Occult Carcinoma in Prophylactic Oophorectomy Specimens: Prevalence and Association With BRCA Germline Mutation Status , 2001, The American journal of surgical pathology.

[43]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[44]  S. Silverberg,et al.  Mucosal Epithelial Proliferation of the Fallopian Tube: Prevalence, Clinical Associations, and Optimal Strategy for Histopathologic Assessment , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[45]  Torn,et al.  Frequency of germline and somatic BRCA1 mutations in ovarian cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  D. Easton,et al.  Contribution of BRCA1 mutations to ovarian cancer. , 1997, The New England journal of medicine.

[47]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[48]  M. Post Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: Implications for intraoperative specimen evaluation , 2012 .

[49]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[50]  R. Bentley,et al.  Cutup – gross description and processing of specimens , 2009 .

[51]  Brian Morrow,et al.  Inpatient hysterectomy surveillance in the United States, 2000-2004. , 2008, American journal of obstetrics and gynecology.

[52]  P. Clement,et al.  The Fallopian Tube and Broad Ligament , 2008 .

[53]  T. Colgan,et al.  Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. , 2006, Gynecologic oncology.

[54]  E. Oliva,et al.  Recommendations for the reporting of fallopian tube neoplasms , 2006, Virchows Archiv.

[55]  M. Beattie,et al.  Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.